X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4789) 4789
Publication (566) 566
Book Review (68) 68
Book Chapter (27) 27
Magazine Article (12) 12
Dissertation (5) 5
Newspaper Article (5) 5
Conference Proceeding (3) 3
Reference (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (4009) 4009
humans (3849) 3849
female (3106) 3106
index medicus (2727) 2727
oncology (2662) 2662
breast neoplasms - drug therapy (2421) 2421
breast cancer (2130) 2130
middle aged (1528) 1528
breast neoplasms - pathology (1465) 1465
antineoplastic combined chemotherapy protocols - therapeutic use (1457) 1457
chemotherapy (1439) 1439
antibodies, monoclonal, humanized (1275) 1275
adult (1259) 1259
cancer (1242) 1242
aged (1207) 1207
receptor, erbb-2 - metabolism (1050) 1050
treatment outcome (927) 927
therapy (893) 893
antibodies, monoclonal - administration & dosage (884) 884
her2 (864) 864
breast neoplasms - metabolism (753) 753
antibodies, monoclonal, humanized - administration & dosage (741) 741
animals (733) 733
antineoplastic agents - therapeutic use (717) 717
care and treatment (661) 661
antineoplastic agents - administration & dosage (660) 660
skin and connective tissue diseases (622) 622
metastasis (603) 603
breast neoplasms - genetics (578) 578
adjuvant chemotherapy (556) 556
research (555) 555
monoclonal-antibody (553) 553
antibodies, monoclonal - therapeutic use (546) 546
trastuzumab - administration & dosage (546) 546
receptor, erbb-2 - genetics (532) 532
cell line, tumor (527) 527
pharmacology & pharmacy (498) 498
disease-free survival (495) 495
survival (489) 489
antineoplastic combined chemotherapy protocols - adverse effects (488) 488
drug therapy (487) 487
mice (480) 480
prognosis (473) 473
cancer therapies (472) 472
paclitaxel - administration & dosage (461) 461
paclitaxel (456) 456
chemotherapy, adjuvant (448) 448
epidermal growth factor (444) 444
taxoids - administration & dosage (431) 431
receptor, erbb-2 - antagonists & inhibitors (426) 426
docetaxel (424) 424
tumors (423) 423
medicine & public health (422) 422
lapatinib (421) 421
breast neoplasms - mortality (415) 415
neoplasm staging (415) 415
neoplasm metastasis (403) 403
antineoplastic agents - adverse effects (399) 399
male (392) 392
breast-cancer (379) 379
neoadjuvant therapy (374) 374
antineoplastic agents (373) 373
aged, 80 and over (367) 367
efficacy (367) 367
trial (358) 358
health aspects (349) 349
receptor, erbb-2 - analysis (349) 349
erbb-2 protein (344) 344
open-label (344) 344
analysis (343) 343
expression (337) 337
antimitotic agents (332) 332
neoplasms (332) 332
metastatic breast-cancer (330) 330
quinazolines - administration & dosage (327) 327
antineoplastic combined chemotherapy protocols - administration & dosage (325) 325
clinical trials (325) 325
safety (319) 319
drug administration schedule (310) 310
antibodies, monoclonal - adverse effects (308) 308
phase-ii (306) 306
hematology, oncology and palliative medicine (301) 301
retrospective studies (297) 297
pertuzumab (294) 294
capecitabine (291) 291
monoclonal antibodies (290) 290
antibodies, monoclonal, humanized - therapeutic use (287) 287
immunohistochemistry (287) 287
patients (285) 285
plus (275) 275
article (272) 272
doxorubicin (271) 271
phase-ii trial (270) 270
antineoplastic agents - pharmacology (266) 266
receptor (265) 265
survival analysis (260) 260
combination (257) 257
deoxycytidine - analogs & derivatives (254) 254
fluorouracil - administration & dosage (253) 253
cardiotoxicity (251) 251
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4514) 4514
Japanese (151) 151
French (60) 60
German (37) 37
Chinese (29) 29
Hungarian (8) 8
Russian (8) 8
Spanish (7) 7
Italian (5) 5
Polish (3) 3
Portuguese (3) 3
Danish (2) 2
Korean (2) 2
Turkish (2) 2
Dutch (1) 1
Hebrew (1) 1
Norwegian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. 2078 - 2099
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3234 - 3241
Journal Article
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5529 - 5537
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth... 
TRIAL | AROMATASE INHIBITOR | THERAPY | ONCOLOGY | SERUM HER-2/NEU | TAMOXIFEN | RESISTANCE | HER2 | COMBINATION | ESTROGEN-RECEPTOR | ENDOCRINE TREATMENT | Receptors, Estrogen - blood | Triazoles - administration & dosage | Triazoles - adverse effects | Confidence Intervals | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Adenocarcinoma - metabolism | Statistics, Nonparametric | Aged, 80 and over | Female | Drug Administration Schedule | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Adenocarcinoma - secondary | Biomarkers, Tumor - blood | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Nitriles - adverse effects | Receptors, Progesterone - blood | Receptor, ErbB-2 - blood | Trastuzumab | Adenocarcinoma - mortality | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 497 - 504
Journal Article